Clarity on the companies, capital and clinical milestones shaping biotech.
OtimoInvest tracks the biotech sector daily — pipeline progress, M&A activity, FDA decisions and the science behind them — and turns it into clear, data-driven briefings. Educational research, not financial advice.
News
Curated biotech headlines from FierceBiotech, STAT, Endpoints and BioPharma Dive — distilled into what matters.
Analysis
Sector briefings on capital flows and clinical catalysts, with charts built from real figures.
Companies to Watch
A growing library of names gaining momentum — and quiet performers flying under the radar.
Pipeline
Blockbuster-potential programs across global biotech, mapped from preclinical to approval.
Glossary
Every term, one place — clinical phases, regulatory pathways and the financial metrics behind them.
Contact
Questions, corrections or coverage suggestions — reach the desk directly.
Educational purposes only. Not financial advice. OtimoInvest is an independent research publication and does not provide personalised investment recommendations.